By Colin Kellaher

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Wednesday said it is ending the development of pimodivir, an investigational antiviral treatment for influenza A infection, after disappointing study results.

Janssen said interim analyses of a Phase 3 study in hospitalized patients with influenza A found that pimodivir in combination with the standard of care was very unlikely to show an added benefit compared to standard-of-care treatment alone.

The company said it is halting the trial in hospitalized patients, along with a parallel study in outpatients with influenza A.

Janssen licensed pimodivir in 2014 from Boston drug maker Vertex Pharmaceuticals Inc. in a deal that included an upfront payment of $30 million, along with contingent development and commercial milestone payments.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 02, 2020 09:38 ET (13:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
過去 株価チャート
から 9 2024 まで 10 2024 Vertex Pharmaceuticalsのチャートをもっと見るにはこちらをクリック
Vertex Pharmaceuticals (NASDAQ:VRTX)
過去 株価チャート
から 10 2023 まで 10 2024 Vertex Pharmaceuticalsのチャートをもっと見るにはこちらをクリック